ACUR Stock — Acura Pharmaceuticals Inc

Acura Pharmaceuticals Inc (ACUR)

Updated October 2, 2026.

ACUR is a Stock. Its deepest 1-year drawdown was 99.0%.

Acura Pharmaceuticals is an innovative drug delivery company that researches, develops, and commercializes pharmaceutical technologies and products addressing safe medication use in the United States, with a portfolio including Oxaydo tablets for pain management and Nexafed products for cold and allergy symptoms. The company operates under collaboration agreements for manufacturing and commercialization of its products. The company does not currently have an established distribution schedule.

ACUR performance

Its deepest 1-year drawdown was 99.0%.

ACUR key facts

Asset type

Stock

Asset class

Equity

Inception date

03/17/1986

Distribution frequency

None

Last close

$0.0001 (as of 2026-10-02)

Market cap

$6,600

Average volume

0.0

Payout ratio

0.0%

Forward P/E

0.0

EPS

$0.00

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) is the latest regular payout annualized by the fund's stated frequency, divided by the last close. Issuers often publish this as “Distribution Rate” on the fact sheet. Trailing-12-month yield is the sum of distributions paid in the last 12 months, split-adjusted, divided by the last close. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ACUR risks and drawbacks

The deepest 1-year drawdown on record here is 99.0%.

Who may consider ACUR — and who may not

It is a weaker fit for investors who need monthly cash flow (ACUR does not currently distribute); investors hunting double-digit covered-call yields. This is educational context, not a recommendation to buy or sell.

Frequently asked questions